European Society of Endocrinology

Corporate Membership Brochure 2027

Shaping the future of endocrinology to improve science, knowledge and health

The European Society of Endocrinology (ESE) represents a community of nearly **6000** individual members, spanning geographical Europe and the globe. Through our partnership with over 50 National Societies that are member of the ESE Council of Affiliated Societies, ESE has a reach and representative status for over **22 500** endocrine health care providers.

Why partner with us?

Endocrine conditions affect millions of people worldwide, spanning all ages, genders and nationalities. Through collaboration between our Committees and Boards, our eight Focus Areas, and our experienced staff team, we deliver a diverse range of activities and initiatives. These are designed to provide opportunities for each career stage, from early and mid-career endocrinologists through to established experts. We also cater to the nurse community, patient advocates and allied health professionals with an interest in endocrinology.

Our tiered Corporate Membership scheme includes options for companies at all stages of development, from pre-clinical research to commercialisation, who share in our commitment to **unite, support and represent the endocrine community through collaboration and the sharing of the best knowledge in endocrine science and medicine**. We view Corporate Membership as a collaborative engagement, providing companies with the opportunity to **connect** with our audiences through participation at events, **share** resources via our website, receive **priority** allocation at our annual congress, and much more, whilst enabling us to continue delivering the high-quality content that ESE is known for.

Costs

ESE Corporate Membership is valid for one calendar year, running from January to December. We welcome multi-year agreements to aid in our planning. Prices are subject to VAT as applicable.

Membership Level	Cost* (per year)	Because Hormones Matter *Optional – see below*
Premium Corporate Membership	€30 000	€5,000
Corporate Membership	€20 000	€5,000
Supporter Membership	€10 000	€5,000

In addition to our Corporate Membership packages, companies are invited to support ESE's Policy and Advocacy (P&A) efforts under the banner of **Because Hormones Matter**. Our P&A work is designed to promote dialogue between key stakeholders on issues such as major health policies relevant to endocrine disease, including **rare diseases, research funding, workforce challenges, drug availability** and other topics relevant to endocrine care in Europe, with a view to driving meaningful change for people affected by endocrine conditions. Through partnerships with our national and European affiliated societies, Patient Advocacy Groups, specialist organisations, industry and our network of policymakers, we can raise the profile of endocrinology at a European level.

World Hormone Day (WHD) takes place on 24 April each year and serves as a focal point in the endocrine calendar, providing a platform from which to deliver our P&A messages. The reach of WHD has grown year on year, with over 120 organisations from 38 countries actively participating in the 2026 edition. Over 275 news articles were issued globally, with a potential reach of 248 million people.

Sponsorship of the Because Hormones Matter initiative includes recognition on the WHD web pages and associated materials, plus the option to invite relevant **members of ESE's leadership/expert communities to attend internal company meetings**, to talk about the importance of endocrinology, how this relates to company priorities, and how ESE and industry can work together to impact the European policy environment.

Our membership

Geographical reach



Top 10 countries

- United Kingdom
- Italy
- France
- Romania
- Ukraine
- Germany
- The Netherlands
- Turkey
- Poland
- Spain

Membership profile



Areas of interest



Corporate Membership Benefits

Premium **(€30,000)**	**Standard** **(€20,000)**	**Supporter** *development/pre-commercial companies* **(€10,000)**
Expert insights		
Option for **one (1) meeting** with identified ESE leadership/Experts (subject to availability)		
Congress		
Opportunity to attend **ECE 2028** industry site visit (Autumn 2027)		
Top tier acknowledgement on site at ECE 2027^	**Second tier** acknowledgement on site at ECE 2027^	**Third tier** acknowledgement on site at ECE 2027^
Two (2) ECE 2027 full congress registrations	**One (1)** ECE 2027 full congress registration	-
First priority allocation on accommodation, sponsorship, education and exhibition opportunities at **ECE 2028***	**Second priority** allocation on accommodation, sponsorship, education and exhibition opportunities at **ECE 2028***	**Third priority** allocation (alongside Congress sponsors) on accommodation, sponsorship, education and exhibition opportunities at **ECE 2028***
Membership		
Three (3) individual ESE memberships**	**Two (2)** individual ESE memberships**	**One (1)** Individual ESE membership**
Membership of **ESE Industry Partnership Board** (see next page)		
Education		
Option to include company medical education/disease awareness resources on ESE website		
NEW: **First** priority option to propose topics for 'Innovation in Endocrinology' webinars (subject to additional sponsorship)	NEW: **Second** priority option to propose topics for 'Innovation in Endocrinology' webinars (subject to additional sponsorship)	NEW: **Third** priority option to propose topics for 'Innovation in Endocrinology' webinars (subject to additional sponsorship)
Visibility		
Option to include industry news on ESE monthly alert emails (subject to ESE approval)		
Listing on all ESE quarterly newsletter issues		
Logo, listing and link to company page on ESE website	Listing and link to company page on ESE website	Listing on ESE website

^In order for acknowledgements to be included in Congress materials, Corporate Membership must be confirmed and agreement finalised no later than 1 March 2027. Agreements finalised after this date may mean that it is not possible to include acknowledgement at the Congress.

*ECE 2028 booking opportunities open in September 2027. Corporate Member companies in 2027 will be given priority allocation for 2028 opportunities, based on agreement to remain as Corporate Member in 2028. Priority allocation on accommodation is for a limited time only (to be confirmed ahead of bookings opening). Sponsorship, education and exhibition priority allocation runs until 31 October 2027.

**nominated company representatives must meet the individual membership criteria as outlined on the ESE membership pages. Individual memberships are subject to approval by the ESE Executive Committee.

The ESE Industry Partnership Board (IPB)

Membership of the IPB is a key benefit of the Premium Corporate Membership package. The IPB was established to ensure strategic engagement between ESE and industry, specifically within the medical and public affairs functions, with member companies demonstrating a long-term commitment to supporting ESE and the wider endocrine discipline. The IPB is jointly chaired by a nominated industry representative and the ESE Chief Executive Officer, ensuring that the board fulfils its purpose to promote two-way dialogue and collaboration.

More information about the Industry Partnership Board can be requested from Natalie Dass.

NEW: 'Innovation in Endocrinology' webinars

In the rapidly evolving field of endocrinology, staying abreast of the latest scientific advancements and innovative treatments is essential for healthcare professionals and researchers. ESE is uniquely positioned to facilitate knowledge exchange and foster collaboration between industry leaders and society members. To this end, in 2026 ESE introduced a new series of webinars under the theme of 'Innovation in Endocrinology', designed to highlight groundbreaking developments in endocrine science and practice.

Our industry partners are at the forefront of these innovations and Corporate Member companies are invited to submit topic suggestions for these webinars, which will be reviewed by ESE's Committees and, if approved, independently developed into a programme fully managed and delivered by ESE.

More information can be requested from Natalie Dass.

ESE Education

ESE offers a number of multi-year educational programmes (see examples here). Corporate Membership is a prerequisite for companies wishing to engage with such programmes, since these form part of our strategic approach to provide education to help to improve the diagnosis, treatment and management of endocrine conditions. In addition, focused events such as the EuroPit Annual Meeting and the new Obesity and Endocrinology School offer an opportunity for companies to connect with experts and up-and-coming KOLs in specific endocrine disciplines.

ESE's Learning Management System (LMS) is now also a key benefit to our members, including over 200 videos and resources designed to support the best endocrine knowledge and practice.

The European Congress of Endocrinology

Corporate Membership provides access to priority allocations at the annual European Congress of Endocrinology (ECE). This ensures that companies can achieve maximum visibility and engagement with over 4,500 endocrine specialists from across Europe and the world. Opportunities range from general sponsorships, to commercial exhibition, to promotional and educational sessions. The congress also offers abstract submission and presentation opportunities, with accepted abstracts published as a supplement to our flagship journal, the *European Journal of Endocrinology* (2025 impact factor: 6.7).

Strength through collaboration

ESE offers a wide range of activities and initiatives to ultimately improve endocrine care. We also encourage our partners to suggest additional activities and approaches to help us achieve this mission, such as educational programmes, events and initiatives, which will be considered by our committees.

For more information about these and other engagement opportunities, or to apply for Corporate Membership, contact Natalie Dass.

Thank you to our 2026 Corporate Members

Premium Corporate Members

ALEXION AstraZeneca Rare Disease

ascendis pharma

ESTEVE Advancing health together

RECORDATI RARE DISEASES Focused on the Few

Corporate Members

AMGEN Rare Disease

BRIDGEBIO

camurus.

Crinetics Pharmaceuticals

Corcept THERAPEUTICS

IPSEN Innovation for patient care

KYOWA KIRIN

NEUROCRINE BIOSCIENCES

Rhythm PHARMACEUTICALS

UNI-PHARMA Pharmaceutical Laboratories S.A.

Supporters

SOLENO THERAPEUTICS